Cargando…
Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?
Since the introduction of imatinib for the treatment of chronic myelogenous leukemia, several oncogenic mutations have been identified in various malignancies that can serve as targets for therapy. More recently, a deeper insight into the mechanism of antitumor immunity and tumor immunoevasion have...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689740/ https://www.ncbi.nlm.nih.gov/pubmed/29156850 http://dx.doi.org/10.18632/oncotarget.21160 |